News | Stem Cell Therapies | November 13, 2015

Protein Reprogramming Offers Potentially Rich Source of Cardiac Repair Heart Cells

New method could provide safer option for regenerative therapy after a heart attack

protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies

November 13, 2015 — A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method for turning fibroblasts — the most common cells in connective tissue — into cardiac progenitor cells (CPCs). The results could lead to a much-needed new source of cells for regenerating the heart. Equally exciting is that the technology also converts the fibroblasts directly to CPCs, skipping an in-between and significantly speeding up the process.

Stem cell transplantation has shown great promise in helping repair a damaged heart, but finding the best source of these cells in quantities large enough for clinical application has been a challenge.  Some success in coaxing induced pluipoent stem cells (iPSCs) to become cardiomyocytes (heart muscle cells) has been accomplished using genetics, but safety issues stemming from the integration of foreign genes into the host and from the use of viral vectors are a concern.

Proteins can briefly modulate the gene expression of the host cells, leading to complete transformation of the parental phenotype using a method that is virus-free and does not introduce any foreign genetic material into the recipient’s system. While researchers have had some success in using proteins to reprogram cells, the number of cells that turned into the intended cell types remains low.

In the SCTM study, a team of scientists from Guangdong General Hospital, Guangzhou Medical University (GMU), Guangdong, China, and Wayne State University (WSU), Detroit, Michigan, reported they overcame this problem by using a simple, non-viral based protein delivery system consisting of four modified transcription factors (GHMT) and three growth factors. When fibroblasts from human skin were reprogrammed to become CPCs, the yield of CPCs was 80 percent. When these cells were then transplanted into rat hearts after a heart attack, cardiac function showed improvement.
Xi-Yong Yu, M.D., Ph.D., of GMU’s Guangdong Cardiovascular Institute, is co-lead investigator of the study. “The resulting CPCs were similar to cardiac progenitors in appearance, colony formation, activation of cardiac marker genes and cardiac lineage differentiation potential,” he said. “We believe this protein reprogramming strategy lays the foundation for future refinements and might provide a source of CPCs for regenerative approaches.”
Co-lead investigator Jianjun Wang, Ph.D., of the Biochemistry and Molecular Biology Department in WSU’s Medical School, added that using undifferentiated CPCs as the building blocks to grow specific types of heart tissue is of great interest for regenerating the myocardium. “However,” he cautioned, “it will be critical to determine whether key physiological properties are faithfully reproduced after reprogramming. Further study is also needed to investigate the characteristics of in vivo differentiated cardiomyocytes and vasculatures [blood vessels] from protein-induced CPCs in their native environment, which might promote survival, maturation and coupling with neighboring cells.”
Yigang Wang, M.D., Ph.D., director of regenerative medicine at University of Cincinnati Medical Center, is another noted researcher focused on the technology involved in producing CPCs with high efficiency. He commented on the Yu-Wang team’s findings, saying that he “hopes that it will lead to a new source of abundant seed cells for cardiac tissue engineering in a clinical setting.”
“While additional research is needed to fully understand the properties of these cells, the results suggest a potentially safer method to generate cardiac progenitor cells for use as a regenerative therapy after a heart attack,” said Anthony Atala, M.D., editor-in-chief of STEM CELLS Translational Medicine, and director of the Wake Forest Institute for Regenerative Medicine.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init